Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Hematology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ERG drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ERG Recombinant Protein (DNA-Binding Domain / Full Length) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for biophysical binding assays. |
View ERG Products |
| Gene Delivery | ERG Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and phenotypic screening. |
View ERG Products |
| Benchmark Ab | Anti-ERG Recombinant Antibody Recombinant positive control sequence verified for Western Blot, IHC, and ChIP validation. |
View ERG Products |
| Validator | ERG siRNA Set For target knockdown verification and functional rescue assays. |
View ERG Products |
| Related Target A | TMPRSS2 Crucial fusion partner (TMPRSS2-ERG) in over 50% of prostate cancers; vital for disease-state modeling. |
View TMPRSS2 Products |
| Related Target B | AR (Androgen Receptor) Drives TMPRSS2-ERG expression; key node for combination therapy and resistance studies. |
View AR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Transcription Factor target accessibility | Truncated functional domains (DBD) designed with high purity (>95%) for SPR/FP assay stability. |
| ETS family selectivity (FLI1/ETS1 off-target screening) | Homolog panel proteins strictly verified by mass spectrometry and sequence alignment. |
| Lack of Controls | Clinical-grade benchmark antibodies included in the portfolio. |
| False Positives in Small Molecule Screen | Sequence-verified siRNA sets included for phenotypic validation. |
Live ERG R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ERG therapeutics is intensifying, with major players shifting focus from traditional small molecules to targeted protein degradation (PROTACs) and RNA-targeting modalities. As first-generation direct inhibitors reach preclinical and early clinical milestones, the next wave of R&D is targeting the protein-protein interactions (PPI) of ERG with co-activators and transcriptional machinery to overcome the historical "undruggable" nature of transcription factors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTAC / Degrader | Arvinas, Kymera Therapeutics | Prostate Cancer (CRPC) | Ternary Complex Validation (Need high-purity full-length ERG & E3 ligases) |
| Small Molecule PPI Inhibitor | Deciphera, Novartis | Ewing Sarcoma, AML | Biophysical Binding Assays (Need sequence-verified DNA-binding domains) |
| siRNA / Oligonucleotide | Alnylam, Arrowhead | Solid Tumors | In vitro Knockdown Validation (Need validated siRNA control sets) |